@article{TLCR486,
author = {Paul Zarogoulidis and Kalliopi Domvri and Haidong Huang and Konstantinos Zarogoulidis},
title = {Gene therapy for lung cancer malignant pleural effusion: current and future nano-biotechnology},
journal = {Translational Lung Cancer Research},
volume = {1},
number = {4},
year = {2012},
keywords = {},
abstract = {Gene therapy has been applied to malignant pleural effusion derived from several types of cancer (colon, breast, lung cancer, mesothelioma, ovarian and liver) (1-5). Successful management has been established either with p53 tumor suppression gene therapy (4,5) or gene therapy as immunotherapy (1,3) and currently with pro-drug transformation (antibiotic) to active chemotherapy compound (2). All studies administered the nanocomplexe (viral vector/plasmid DNA) through a tunneled intrapleural catheter to induce local disease management. The nanoparticle used to deliver gene therapy in all previous presented studies was a viral vector. Viral vectors are known to stimulate the immune system and therefore formulate neutralizing antibodies (Nabs) against the nanocomplex (6).},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/486}
}